Heteronemin suppresses EGF‑induced proliferation through the PI3K/PD‑L1 signaling pathways in cholangiocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Epidermal growth factor (EGF) receptor signaling drives cancer cell proliferation.
• EGF-induced growth involves phosphoinositide 3-kinase (PI3K) and programmed cell death ligand 1 (PD-L1) pathways.
• Cholangiocarcinoma is a cancer where EGF signaling plays a role.

Purpose of the Study:

• To investigate the molecular mechanisms of EGF-induced proliferation in cholangiocarcinoma cells.
• To evaluate the anti-cancer effects of heteronemin, an integrin αvβ3 antagonist.
• To determine if heteronemin can reverse EGF-stimulated signaling and proliferation.

Main Methods:

• Quantitative PCR (qPCR) and Western blotting to analyze gene expression and protein levels.
• Cell viability assays to assess proliferation.
• Investigated the role of PI3K pathway inhibition.

Main Results:

• EGF significantly increased cholangiocarcinoma cell proliferation and gene expression.
• Heteronemin demonstrated cytotoxic effects and reversed EGF-induced proliferation.
• Heteronemin inhibited PI3K activation and PD-L1 expression.
• Blocking PI3K activity enhanced heteronemin's inhibitory effects.

Conclusions:

• EGF promotes cholangiocarcinoma cell growth through PI3K and PD-L1 pathways.
• Heteronemin effectively inhibits EGF-induced proliferation by targeting these pathways.
• Heteronemin represents a potential therapeutic agent for cholangiocarcinoma.